TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

XIPERE

TRIAMCINOLONE ACETONIDE Corticosteroid Hormone Receptor Agonists
Ophthalmology Approved 2021-10-22
1
Indication
--
Phase 3 Trials
4
Years on Market

Details

Status
Prescription
First Approved
2021-10-22
Routes
INJECTION
Dosage Forms
SUSPENSION

Companies

Active Ingredient: TRIAMCINOLONE ACETONIDE

XIPERE Approval History

Loading approval history...

What XIPERE Treats

2 indications

XIPERE is approved for 2 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Macular Edema
  • Uveitis
Source: FDA Label

Drugs Similar to XIPERE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

OZURDEX
DEXAMETHASONE
2 shared
AbbVie
Shared indications:
Macular EdemaUveitis
ABRILADA
ADALIMUMAB-AFZB
1 shared
Pfizer
Shared indications:
Uveitis
AHZANTIVE
AFLIBERCEPT-MRBB
1 shared
FORMYCON AG
Shared indications:
Macular Edema
AMJEVITA
ADALIMUMAB-ATTO
1 shared
Amgen
Shared indications:
Uveitis
BYOOVIZ
RANIBIZUMAB-NUNA
1 shared
SAMSUNG BIOEPIS CO LTD
Shared indications:
Macular Edema
CYLTEZO
ADALIMUMAB-ADBM
1 shared
Boehringer Ingelheim
Shared indications:
Uveitis
DIFLUPREDNATE
DIFLUPREDNATE
1 shared
Cipla
Shared indications:
Uveitis
DUREZOL
DIFLUPREDNATE
1 shared
Novartis
Shared indications:
Uveitis
EYDENZELT
AFLIBERCEPT-BOAV
1 shared
CELLTRION INC
Shared indications:
Macular Edema
HADLIMA
ADALIMUMAB-BWWD
1 shared
SAMSUNG BIOEPIS CO LTD
Shared indications:
Uveitis
HUMIRA
ADALIMUMAB
1 shared
AbbVie
Shared indications:
Uveitis
HYRIMOZ
ADALIMUMAB-ADAZ
1 shared
Novartis
Shared indications:
Uveitis
ILUVIEN
FLUOCINOLONE ACETONIDE
1 shared
ALIMERA SCIENCES INC
Shared indications:
Uveitis
PAVBLU
AFLIBERCEPT-AYYH
1 shared
Amgen
Shared indications:
Macular Edema
RETISERT
FLUOCINOLONE ACETONIDE
1 shared
BAUSCH AND LOMB
Shared indications:
Uveitis
SIMLANDI
ADALIMUMAB-RYVK
1 shared
ALVOTECH USA INC
Shared indications:
Uveitis
TRIESENCE
TRIAMCINOLONE ACETONIDE
1 shared
HARROW EYE
Shared indications:
Uveitis
YUFLYMA
ADALIMUMAB-AATY
1 shared
CELLTRION
Shared indications:
Uveitis
YUSIMRY
ADALIMUMAB-AQVH
1 shared
COHERUS BIOSCIENCES INC
Shared indications:
Uveitis
YUTIQ
FLUOCINOLONE ACETONIDE
1 shared
ALIMERA SCIENCES INC
Shared indications:
Uveitis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

XIPERE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

XIPERE ® (triamcinolone acetonide injectable suspension) 40 mg/mL is indicated for the treatment of macular edema associated with uveitis. XIPERE ® is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

XIPERE Patents & Exclusivity

Latest Patent: Apr 2040

Patents (4 active)

US12419833 Expires Apr 16, 2040
US9937075 Expires May 2, 2034
US9636332 Expires Nov 8, 2033
US8636713 Expires May 2, 2027
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.